Welcome to our dedicated page for Argan SEC filings (Ticker: AGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Argan, Inc. (NYSE: AGX) is a Delaware corporation whose common stock is listed on the New York Stock Exchange, and it files periodic and current reports with the U.S. Securities and Exchange Commission. This SEC filings page brings together Argan’s Forms 10-K and 10-Q, as well as its frequent Form 8-K current reports, which disclose material events such as financial results, major project contracts and dividend declarations.
In its Form 8-K filings, Argan reports items like quarterly earnings releases under results of operations and financial condition, regular quarterly cash dividend announcements, and significant EPC contract awards received by subsidiaries such as Gemma Power Systems and Atlantic Projects Company. These filings also confirm key corporate details, including Argan’s state of incorporation, the AGX trading symbol and its New York Stock Exchange listing.
For investors and analysts, Argan’s annual reports on Form 10-K and quarterly reports on Form 10-Q provide more comprehensive information on segment performance, project backlog, risk factors and accounting policies, while current reports on Form 8-K highlight specific developments between reporting periods. Filings may also describe how new EPC contracts, full notices to proceed and backlog additions affect the company’s future activity.
On this page, AI-powered tools summarize lengthy SEC documents, highlight the main points from Argan’s 10-K and 10-Q filings, and explain the significance of individual 8-K items, such as dividend changes or large contract awards. Users can also review insider and executive-related filings like Form 4, along with proxy materials, to gain additional insight into Argan’s governance and equity activity.
Argan Inc. director Cynthia A. Flanders reported an open-market sale of company stock. On January 21, 2026, she sold 19,000 shares of Argan common stock at an average price of $386.70 per share. After this transaction, she directly owned 26,207 shares of Argan common stock. The filing classifies her as a director and shows that the transaction involved non-derivative securities only, with no associated options or other derivative instruments.
Argan Inc. director John R. Jeffrey Jr. reported option exercises and a share sale. On January 16, 2026, he exercised an option to purchase 10,000 shares of Argan common stock at $45.75 per share using a net settle method, resulting in 8,636 shares of common stock being acquired. On January 20, 2026, he sold 2,700 shares of Argan common stock on the open market at an average price of $380.60 per share. After these transactions, he directly owned 13,192 shares of common stock and indirectly owned 8,000 shares through a John R. Jeffrey IRA, and held 11,500 stock options following the option exercise.
Argan Inc. director William F. Leimkuhler reported a sale of company stock. On January 16, 2026, he sold 11,044 shares of Argan Inc. common stock at an average price of $379.15 per share, as shown in the Form 4 filing.
After this transaction, he beneficially owned 49,939 shares of Argan Inc. common stock in direct ownership. This filing reflects a routine insider transaction and does not by itself describe any change in the company’s operations or financial performance.
An insider of the issuer of AGX filed a Form 144 notice to sell 2,700 shares of common stock. The planned sale has an aggregate market value of 1,002,726 and is expected to be executed around 01/20/2026 through Charles Schwab & Co. Inc. on the NYSE.
The 2,700 shares were acquired on 12/16/2025 via a time-based restricted stock issuance from the issuer, with the full amount received on that date. The filing also notes that 13,873,410 shares of the issuer’s common stock were outstanding, providing context for the size of the planned sale.
A shareholder of AGX has filed a notice of proposed sale under Rule 144 for up to 19,000 shares of common stock. The shares are to be sold through Merrill Lynch, with an aggregate market value of $5,880,500, and the sale is targeted to occur around January 20, 2026 on the NYSE.
The notice also shows that 13,873,410 shares of this class were outstanding and that the seller’s position comes from a stock option acquired on January 13, 2026, involving 26,079 shares settled via a cashless transaction on January 14, 2026.
Argan Inc. director Cynthia Flanders reported multiple stock option exercises in Argan Inc. common stock. On January 13, 2026, she exercised four "Option to Purchase Common Stock" awards covering 10,000 shares at $40.15 per share, 10,000 shares at $45.75 per share, 5,000 shares at $37.13 per share, and 5,000 shares at $35.72 per share, each described as using the net settle method.
Following these exercises, her directly held common stock increased in steps to 45,207 shares. The Form 4 also shows that after the transactions she continued to hold derivative positions in options to purchase Argan common stock, including 21,500, 11,500, 6,500 and 1,500 option shares at the respective exercise prices.
Argan Inc. director William F. Leimkuhler reported two open-market sales of the company’s common stock. On January 12, 2026, he sold 2,164 shares at an average price of $318.28 per share, and on January 13, 2026, he sold 4,212 shares at an average price of $320.53 per share, for a total of 6,376 shares sold.
After these transactions, Leimkuhler directly beneficially owned 60,983 shares of Argan common stock. The filing classifies him as a director and indicates the form is filed by one reporting person.
Argan Inc. director Peter W. Getsinger reported multiple stock transactions in early January 2026. On January 7, 2026, he sold 4,000 shares of Argan common stock on the open market at an average price of $328.34 per share. That same day, he exercised a stock option to purchase 7,500 shares at an exercise price of $40.15 per share using the net settle method, resulting in 6,595 shares of common stock being acquired.
On January 8, 2026, Getsinger sold another 6,595 shares on the open market at an average price of $313.71 per share. Following these transactions, he directly owned 7,847 shares of Argan common stock and held 14,000 stock options to purchase additional shares.
Argan Inc. director William F. Leimkuhler reported multiple stock option exercises in the company’s common stock. On January 7, 2026, he exercised options granted between December 2019 and December 2022 to purchase blocks of 10,000 and 5,000 shares at exercise prices of $40.15, $45.75, $37.13, and $35.72 per share, using the net settle method. These exercises increased his directly held common stock, and following the reported transactions he directly owned 67,359 Argan shares.
A holder of AGX common stock has filed a notice under Rule 144 to sell 6,595 shares through Morgan Stanley Smith Barney LLC on the NYSE, with an indicated aggregate market value of $2,068,918.11. The sale follows an exercise of stock options under a registered plan on 01/07/2026, paid in cash for the same number of shares.
The notice reports 13,873,410 common shares outstanding. It also lists recent sales for the same person over the past three months: 6,493 shares on 10/20/2025 for $1,911,329.25, 2,000 shares on 10/17/2025 for $584,000.00, and 4,000 shares on 01/07/2026 for $1,313,353.88. The seller represents that they are not aware of undisclosed material adverse information about the issuer.